Humanized liver data Targeting partners in gene therapies or liver disease research, Yecuris offers highly humanized FRG liver models with over 70% human hepatocyte replacement, presenting a compelling data-driven platform for preclinical efficacy and safety testing.

Small to mid market focus With a team size of 11-50 and revenue in the 10–25 million range, Yecuris sits alongside mid-sized biotech CROs, indicating a potential fit for collaborations, project-based services, and scalable animal model offerings.

Diversified research applications Their FRG platform supports liver-related studies across metabolism, toxicology, and liver disease cures, suggesting cross-sell opportunities into hepatology, NASH programs, and small molecule screening.

Digital engagement channels Active use of LinkedIn Ads, Google Ads, HubSpot, and Smartsheet indicates strong outbound and inbound marketing potential; consider targeted campaigns focusing on liver disease, hepatocyte data, and translational models.

Growth and partnership potential Compared to peers like Taconic and Canopy Biosciences, Yecuris presents a lean, research-focused profile with potential for strategic collaborations, joint studies, or contract research expansions to scale their FRG offerings.